Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (b-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: tisagenlecleucel, inebilizumab, obecabtagene autoleucel +11 | 0.90 |
| trials ClinicalTrials.gov | 2 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 30 Parkinson's papers of 18,691 | 0.55 |
| pathways Reactome | 6 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 3140
Sealed predictions
- CD19 in dopamine neurons, braak-0.39 (p 0.303) → -0.41 (p 0.273)receipt 3147
Swarm cases
receipt 3147: CD19 in dopamine neurons, braak
- power
- full sample -0.48 (p 0.046, n 18), 95% CI -0.77 to -0.01. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.44 (p 0.064, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.58 (p 0.011, n 18). not the mix.
- skeptic
- leave-one-out range -0.61 to -0.41, sign flips 0; without severely affected donors -0.48 (p 0.046, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD19 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts